Why This ChemoCentryx Analyst Is Bullish
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan.
The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on shares of ChemoCentryx, Inc. with a $28 price target.